瘦素及ghrelin基因多态性与精神分裂症患者利培酮所致代谢变化的关系

Objective To investigate the changes of body weight and metabolism related indexes after risperidone treatment in schizophrenia and to analyze the relationship of leptin gene 2548G/A polymorphism and polymorphism of ghrelin gene leucine 72 methionine (Leu72Met) with changes in body weight and metabolism related indicators. Methods Sixty-eight patients with schizophrenia were treated with risperidone monotherapy for 10 weeks. The metabolic indexes including body mass index (BMI), waist circumference, fasting blood glucose and blood lipid levels were measured at 4 and 10 weeks after treatment. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was used to detect the polymorphisms of leptin gene and ghrelin gene. Results The patients' body weight, blood glucose and blood lipids were significantly increased during treatment (P<0.05). The ghrelin gene Leu72Met polymorphism was associated with changes in blood glucose (F=4.269, P=0.042), and the Leu72 allele carrier had a higher fasting blood glucose level. The polymorphisms of leptin gene and two genes were not related to changes in body weight or metabolic indexes (P> 0.05). Conclusion During the acute phase of risperidone treatment, patients may have different levels of body weight, blood glucose and blood lipid. The ghrelin gene Leu72 allele may be a risk factor for hyperglycemia in patients with schizophrenia treated with risperidone.